Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Androgen-Independent Prostatic Cancer Clear all
Completed Phase 2 Interventional

Flavopiridol in Treating Patients With Recurrent Prostate Cancer

NCT00003256
View directory record Official record
Conditions
Prostate Cancer
Interventions
alvocidib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
4
States / cities
Duarte, California • Sacramento, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Jul 23, 2026, 10:34 AM EDT
Completed Phase 2 Interventional

Cilengitide in Treating Patients With Metastatic Prostate Cancer

NCT00103337
View directory record Official record
Conditions
Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
cilengitide, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Jul 23, 2026, 10:34 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients

NCT00654186
View directory record Official record
Conditions
Prostate Cancer
Interventions
Revlimid
Drug
Lead sponsor
Oncology Specialists, S.C.
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Niles, Illinois • Park Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Jul 23, 2026, 10:34 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer

NCT00014352
View directory record Official record
Conditions
Prostate Cancer, Thromboembolism
Interventions
docetaxel, doxorubicin hydrochloride, estramustine phosphate sodium, ketoconazole, warfarin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Jul 23, 2026, 10:34 AM EDT
Completed Phase 2 Interventional

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT05848011
View directory record Official record
Conditions
Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent, Androgen-Insensitive Prostatic Cance, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Immunotherapy, Immune Checkpoint Inhibitor, Inhibitory Checkpoint Molecule
Interventions
lorigerlimab, docetaxel, Prednisone
Biological · Drug
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older · Male only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
Miami, Florida • Orlando, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 23, 2026, 10:34 AM EDT
Completed Phase 2 Interventional

Study of Oxaliplatin and Taxotere in Prostate Cancer

NCT00260611
View directory record Official record
Conditions
Prostate Cancer
Interventions
Oxaliplatin, Taxotere
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Jul 23, 2026, 10:34 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer

NCT00780975
View directory record Official record
Conditions
Prostate Cancer
Interventions
Aplidin (plitidepsin)
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Ann Arbor, Michigan • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Jul 23, 2026, 10:34 AM EDT
Not listed Phase 1Phase 2 Interventional

Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer

NCT00121095
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Samarium Sm-153 lexidronam + Docetaxel
Drug
Lead sponsor
Cytogen Corporation
Industry
Eligibility
Male only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 20, 2007 · Synced Jul 23, 2026, 10:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

NCT00878436
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms
Interventions
Panobinostat, Bicalutamide
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
4
States / cities
New Brunswick, New Jersey • Lake Success, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Jul 23, 2026, 10:34 AM EDT
Completed Phase 2 Interventional

Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases

NCT00080678
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
Docetaxel, Imatinib Mesylate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Jul 23, 2026, 10:34 AM EDT
Completed Phase 2 Interventional

PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy

NCT00078585
View directory record Official record
Conditions
Prostate Cancer
Interventions
PROSTVAC®-VF/TRICOM™
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
47
States / cities
Homewood, Alabama • Anchorage, Alaska • Fresno, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Jul 23, 2026, 10:34 AM EDT
Completed Phase 1 Interventional

A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

NCT05293496
View directory record Official record
Conditions
Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma, Pancreatic Ductal Carcinoma, Hepatocellular Cancer, Epithelial Ovarian Cancer, Renal Cell Carcinoma
Interventions
vobramitamab duocarmazine, lorigerlimab
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Sarasota, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jul 23, 2026, 10:34 AM EDT
Completed Phase 2 Interventional

Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer

NCT00258284
View directory record Official record
Conditions
Prostate Cancer
Interventions
capecitabine, docetaxel
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Jul 23, 2026, 10:34 AM EDT
Completed Phase 2 Interventional Results available

Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients

NCT00919035
View directory record Official record
Conditions
Prostate Cancer
Interventions
torisel
Drug
Lead sponsor
Oncology Specialists, S.C.
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Niles, Illinois • Park Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2014 · Synced Jul 23, 2026, 10:34 AM EDT
Terminated Phase 2 Interventional

Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer

NCT00019695
View directory record Official record
Conditions
Stage IV Prostate Cancer, Bone Metastases, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Interventions
alendronate sodium, ketoconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Timeline
1999 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Jul 23, 2026, 10:34 AM EDT
Completed Phase 2 Interventional Results available

AZD2171 to Treat Prostate Cancer

NCT00436956
View directory record Official record
Conditions
Prostate Cancer
Interventions
Magnetic Resonance Imaging (DCE-MRI), AZD2171, Prednisone
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Jul 23, 2026, 10:34 AM EDT
Completed Phase 3 Interventional Results available

Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer

NCT00519285
View directory record Official record
Conditions
Prostatic Neoplasms, Neoplasm Metastasis
Interventions
Aflibercept, Placebo (for aflibercept), Docetaxel, Prednisone or Prednisolone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Jul 23, 2026, 10:34 AM EDT
Active, not recruiting Phase 4 Interventional

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

NCT03016741
View directory record Official record
Conditions
Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer, Hormone-Refractory Prostate Cancer
Interventions
GnRH agonist/antagonist, Prednisone, Abiraterone Acetate, Enzalutamide
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Jul 23, 2026, 10:34 AM EDT
Not listed No phase listed Observational

Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving Chemotherapy

NCT00133900
View directory record Official record
Conditions
Hormone Refractory Prostate Cancer, Prostate Cancer
Interventions
Phlebotomy
Procedure
Lead sponsor
Immunicon
Industry
Eligibility
18 Years and older · Male only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2009 · Synced Jul 23, 2026, 10:34 AM EDT
Completed Phase 1 Interventional

A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Cancer

NCT00052000
View directory record Official record
Conditions
Prostate Cancer
Interventions
MLN2704 (DM1 conjugated monoclonal antibody MLN591)
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2007 · Synced Jul 23, 2026, 10:34 AM EDT
Completed Phase 1 Interventional

Ketoconazole Plus Docetaxel to Treat Prostate Cancer

NCT00032825
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Ketaconazole, Docetaxel
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Jul 23, 2026, 10:34 AM EDT
Completed Phase 2 Interventional Results available

Cilengitide in Treating Patients With Prostate Cancer

NCT00121238
View directory record Official record
Conditions
Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions
cilengitide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Jul 23, 2026, 10:34 AM EDT
Terminated Phase 1 Interventional

Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer

NCT00096304
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, epirubicin hydrochloride
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Jul 23, 2026, 10:34 AM EDT
Completed Phase 2 Interventional

Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer

NCT00182741
View directory record Official record
Conditions
Prostate Cancer
Interventions
calcitriol, mitoxantrone hydrochloride, prednisone
Dietary Supplement · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Jul 23, 2026, 10:34 AM EDT